# BN80927 in Patients With Advanced Malignant Solid Tumors

> **NCT01435096** · PHASE1 · COMPLETED · sponsor: **Ipsen** · enrollment: 56 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** BN80927

## Key facts

- **NCT ID:** NCT01435096
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435096, "BN80927 in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01435096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*